COVID-19-Associated Multisystem Inflammatory Syndrome in Children - United States, March-July 2020
- PMID: 32790663
- PMCID: PMC7440126
- DOI: 10.15585/mmwr.mm6932e2
COVID-19-Associated Multisystem Inflammatory Syndrome in Children - United States, March-July 2020
Erratum in
-
Erratum: Vol. 69, No. 32.MMWR Morb Mortal Wkly Rep. 2020 Sep 4;69(35):1229. doi: 10.15585/mmwr.mm6935a6. MMWR Morb Mortal Wkly Rep. 2020. PMID: 32881853 Free PMC article. No abstract available.
Abstract
In April 2020, during the peak of the coronavirus disease 2019 (COVID-19) pandemic in Europe, a cluster of children with hyperinflammatory shock with features similar to Kawasaki disease and toxic shock syndrome was reported in England* (1). The patients' signs and symptoms were temporally associated with COVID-19 but presumed to have developed 2-4 weeks after acute COVID-19; all children had serologic evidence of infection with SARS-CoV-2, the virus that causes COVID-19 (1). The clinical signs and symptoms present in this first cluster included fever, rash, conjunctivitis, peripheral edema, gastrointestinal symptoms, shock, and elevated markers of inflammation and cardiac damage (1). On May 14, 2020, CDC published an online Health Advisory that summarized the manifestations of reported multisystem inflammatory syndrome in children (MIS-C), outlined a case definition,† and asked clinicians to report suspected U.S. cases to local and state health departments. As of July 29, a total of 570 U.S. MIS-C patients who met the case definition had been reported to CDC. A total of 203 (35.6%) of the patients had a clinical course consistent with previously published MIS-C reports, characterized predominantly by shock, cardiac dysfunction, abdominal pain, and markedly elevated inflammatory markers, and almost all had positive SARS-CoV-2 test results. The remaining 367 (64.4%) of MIS-C patients had manifestations that appeared to overlap with acute COVID-19 (2-4), had a less severe clinical course, or had features of Kawasaki disease.§ Median duration of hospitalization was 6 days; 364 patients (63.9%) required care in an intensive care unit (ICU), and 10 patients (1.8%) died. As the COVID-19 pandemic continues to expand in many jurisdictions, clinicians should be aware of the signs and symptoms of MIS-C and report suspected cases to their state or local health departments; analysis of reported cases can enhance understanding of MIS-C and improve characterization of the illness for early detection and treatment.
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
Figures
Similar articles
-
Multisystem Inflammatory Syndrome in Children in New York State.N Engl J Med. 2020 Jul 23;383(4):347-358. doi: 10.1056/NEJMoa2021756. Epub 2020 Jun 29. N Engl J Med. 2020. PMID: 32598830 Free PMC article.
-
Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection - United Kingdom and United States, March-August 2020.MMWR Morb Mortal Wkly Rep. 2020 Oct 9;69(40):1450-1456. doi: 10.15585/mmwr.mm6940e1. MMWR Morb Mortal Wkly Rep. 2020. PMID: 33031361 Free PMC article.
-
Multisystem Inflammatory Syndrome in U.S. Children and Adolescents.N Engl J Med. 2020 Jul 23;383(4):334-346. doi: 10.1056/NEJMoa2021680. Epub 2020 Jun 29. N Engl J Med. 2020. PMID: 32598831 Free PMC article.
-
Multisystem Inflammatory Syndrome in Children (MIS-C).Curr Allergy Asthma Rep. 2022 May;22(5):53-60. doi: 10.1007/s11882-022-01031-4. Epub 2022 Mar 22. Curr Allergy Asthma Rep. 2022. PMID: 35314921 Free PMC article. Review.
-
Shock and Myocardial Injury in Children With Multisystem Inflammatory Syndrome Associated With SARS-CoV-2 Infection: What We Know. Case Series and Review of the Literature.J Intensive Care Med. 2021 Apr;36(4):392-403. doi: 10.1177/0885066620969350. Epub 2020 Nov 5. J Intensive Care Med. 2021. PMID: 33148089 Review.
Cited by
-
Evaluation of clinical and laboratory findings in MIS-C patients associated with COVID-19: An experience from the Northwest of Iran.PLoS One. 2024 Nov 21;19(11):e0313843. doi: 10.1371/journal.pone.0313843. eCollection 2024. PLoS One. 2024. PMID: 39570835 Free PMC article.
-
An Overview of Pediatric Pulmonary Complications During COVID-19 Pandemic: A Lesson for Future.Immun Inflamm Dis. 2024 Nov;12(11):e70049. doi: 10.1002/iid3.70049. Immun Inflamm Dis. 2024. PMID: 39508631 Free PMC article. Review.
-
Proteomic Signatures of Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19: A Narrative Review.Children (Basel). 2024 Sep 26;11(10):1174. doi: 10.3390/children11101174. Children (Basel). 2024. PMID: 39457139 Free PMC article. Review.
-
A Study of Hydroelectrolytic and Acid-Base Disturbances in MIS-C Patients: A Perspective on Antidiuretic Hormone Secretion.Curr Issues Mol Biol. 2024 Oct 16;46(10):11438-11459. doi: 10.3390/cimb46100681. Curr Issues Mol Biol. 2024. PMID: 39451561 Free PMC article.
-
Identification of COVID-19-Associated Hepatitis in Children as an Emerging Complication in the Wake of SARS-CoV-2 Infections: Ambispective Observational Study.JMIRx Med. 2024 Oct 11;5:e48629. doi: 10.2196/48629. JMIRx Med. 2024. PMID: 39392692 Free PMC article.
References
-
- Belhadjer Z, Méot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation 2020. E-pub May 17, 2020. - PubMed
-
- Linzer DA, Lewis JB. poLCA: An R package for polytomous variable latent class analysis. J Stat Softw 2011;42:1–29. 10.18637/jss.v042.i10 - DOI
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous

